Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment (CogMCI)

August 27, 2013 updated by: Chul Soo Kim, Inha University Hospital

A Multicenter, Randomized Trial to Assess Efficacy of Home-based and Group Cognitive Intervention Programs in Amnestic Mild Cognitive Impairment

  • There will be a significant difference in cognitive function between cognitive intervention group (group therapy) and a wait list control group.
  • There will be a significant difference in cognitive function between a home-based cognitive intervention group and a wait list control group.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The change of Modified ADAS-cog score from the baseline to post-intervention will be compared between the cognitive intervention group and wait list control group.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
293

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Ansan, Korea, Republic of
        • Korea University Medical College
      • Bucheon, Korea, Republic of, 420-767
        • Soonchunhyang University Hospital
      • Bucheon, Korea, Republic of
        • Bucheon St. Mary's Hospital, The Catholic University of Korea
      • Busan, Korea, Republic of
        • Pusan National University Hospital
      • Busan, Korea, Republic of, 602-715
        • DongA University Hospital
      • Daejun, Korea, Republic of, 302-799
        • Daejun Eulji University Hopistal
      • Goyang, Korea, Republic of
        • NHIC Ilsan Hospital
      • Goyang, Korea, Republic of, 412-270
        • Myongji Hospital
      • Incheon, Korea, Republic of, 400-711
        • Inha Univeristy Hospital
      • Jeju, Korea, Republic of
        • Jeju National University Hospital
      • Pusan, Korea, Republic of
        • Maryknoll Hospital
      • Seongnam, Korea, Republic of
        • bobath Memorial Hospital
      • Seoul, Korea, Republic of
        • Inje University Sanggye Paik Hospital
      • Seoul, Korea, Republic of, 135-710
        • Sungkyunkwan University, Samsung Seoul Hospital
      • Seoul, Korea, Republic of, 431-060
        • Asan Medical Center, Psychiatry
      • Seoul, Korea, Republic of
        • Konkuk University Medical Cener
      • Suwon, Korea, Republic of
        • Ajou University Hospital
      • Yongin, Korea, Republic of
        • Hyoja Geriatric Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 50 to 85 years of age
  • memory complaint corroborated by a participant and an informant
  • delayed recall score on the Seoul Verbal Learning Test (SVLT) below 1.0 standard deviations from the mean of the age and education-normative values among the Korean population
  • Global CDR score is 0.5, Memory CDR score is 0.5 or 1.
  • above 1.5 standard deviations from the mean of normative data of the respective age- and education-matched population on the Korean Mini-Mental State Examination
  • normal functional activities
  • not diagnosed with dementia
  • Modified Hachinski Ischemic Score (HIS): 0-4
  • brain magnetic resonance imaging or CT showing no clinical evidence of other diseases (i.e., normal pressure hydrocephalus, brain tumor, cerebrovascular disease) capable of producing cognitive impairment.
  • Subjects are also required to have a reliable caregiver who meet the patient at least once a week and is sufficiently familiar with the patient to provide the investigator with accurate information.
  • He/She can read and write
  • written informed consent

Exclusion Criteria:

  • any patient who were involved in other clinical trials or treated with experimental drug within 4 weeks
  • any patients with any severe or unstable medical disease that may prevent the patient from completing all study requirements (i.e., unstable or severe asthma or cardiovascular disease, active gastric ulcer, severe hepatic or renal disease)
  • any patients with clinically significant laboratory abnormalities such as an abnormal thyroid function test, abnormal low level of vitamin B12 or folate, or positive venereal disease research laboratory test
  • any patients with any primary neurodegenerative disorder or psychiatric disorder other than AD (i.e., Parkinson's disease, schizophrenia, or major depressive disorder)
  • any patients with any history of drug or alcohol addiction during the past 10 years
  • any hearing or visual impairment that can disturb the efficient evaluation of the patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Group cognitive intervention
The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
Other: group cognitive intervention
The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
Active Comparator: Home-based cognitive intervention
The participants will do their homework for 30 minutes every business days for 12 weeks.
Other: Home-based cognitive intervention
The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
No Intervention: Wait list Control
They will participate in cognitive intervention after ending this study.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Modified Alzheimer's Disease Assessment Scale-Cognitive subscale(ADAS-cog)
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
story recall test
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Digit span forward and backward
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Word fluency test
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
color-word stroop test
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Digit symbol test
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
prospective memory test
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Mini-Mental State Examination
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
CDR-SB
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
K-AD8
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
PRMQ
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
MMQ-Strategy
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
QOL-AD
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Geriatric Depression Scale-short form
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Bayer ADL
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
CGA-NPI
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up
Subjective cognitive assessment
Time Frame: postintervention, 12 weeks follow-up, and 24 weeks follow-up
postintervention, 12 weeks follow-up, and 24 weeks follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Inha University Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Eisai Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Seong H Choi, MD, PhD, Inha University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2013

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2013

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 20, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2011

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 24, 2011

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 28, 2013

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 27, 2013

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CogMCI study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings